Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.
Its lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine.

Market capitalization(2018-06-15)

$1.2 B

Type

Public

Bothell, US

Founded

2004

Size (employees)

176 (est)

Website

alderbio.com

Alder BioPharmaceuticals was founded in 2004 and is headquartered in Bothell, US

Report incorrect company information

Key People/Management at Alder BioPharmaceuticals

John Latham

Chief Scientific Officer

Larry Benedict

Vice President, Finance

Mark Litton

Chief Business Officer and Treasurer

Paul Cleveland

Interim President and Chief Executive Officer

Report incorrect company information

Alder BioPharmaceuticals Office Locations

Alder BioPharmaceuticals has an office in Bothell

Bothell, US (HQ)

11804 North Creek Parkway

Show all (1)

Report incorrect company information

Alder BioPharmaceuticals Financials and Metrics

Alder BioPharmaceuticals Financials

Summary

USD
Net income (Q1, 2018)	(87 m)
EBIT (Q1, 2018)	(85.7 m)
Market capitalization (15-Jun-2018)	1.2 b
Closing share price (15-Jun-2018)	17.7
Cash (31-Mar-2018)	202 m

Alder BioPharmaceuticals's current market capitalization is $1.2 b.

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cost of goods sold			113 k	1.6 m
General and administrative expense	12.5 m	16.7 m	26.1 m	38.1 m
R&D expense	33.4 m	69.6 m	132.8 m	252.9 m
Operating expense total	45.9 m	86.3 m	158.9 m	292.6 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Cost of goods sold								113 k	113 k		683 k
General and administrative expense	3.2 m	2.7 m	3.2 m	3.7 m	3.9 m	4.3 m	6 m	6.5 m	6.2 m	10 m	9.5 m	11.7 m
R&D expense	7 m	9.4 m	7 m	11 m	14.1 m	22.9 m	27.6 m	33.8 m	29.5 m	90.7 m	65.3 m	74 m
Operating expense total	10.2 m	12.1 m	10.2 m	14.7 m	18 m	27.2 m	33.7 m	40.4 m	35.7 m	100.7 m	75.5 m	85.7 m

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	46.8 m	206.5 m	116.2 m	76.9 m
Accounts Receivable	113 k	113 k
Inventories		28.2 m	936 k
Current Assets	60.7 m	322.2 m	393.2 m	287.3 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Cash	12.9 m	70.3 m	57.6 m	209.9 m	408 m	234 m	178 m	230 m	170.6 m	79.7 m	127.8 m	202 m
Accounts Receivable	91 k	57 k	81 k	113 k	113 k	113 k
Inventories								936 k	936 k	936 k	936 k
Current Assets	14.3 m	81.8 m	73.8 m	241.6 m	442.1 m	319.8 m	319.7 m	464.1 m	428 m	310.3 m	246.6 m	340.7 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	8.9 m	(85.5 m)	(156.3 m)	(288.9 m)
Depreciation and Amortization	701 k	751 k	1.7 m	3 m
Inventories		95 k	(936 k)	936 k
Accounts Payable	(312 k)	2.8 m	5.5 m	(2.4 m)

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income	(5.4 m)	(7.4 m)	28.6 m	(14.7 m)	(17.7 m)	(27 m)	(33.4 m)	(38.9 m)	(35.1 m)	(100.3 m)	(87 m)
Depreciation and Amortization											801 k
Inventories								936 k	936 k	936 k
Accounts Payable		2.8 m	1.8 m	2.2 m	2.4 m	7.7 m	9.6 m	8.4 m	5.7 m	20.3 m	5.3 m